Medicare's $50 GLP‑1 pilot leaves out people whose diagnoses the drugs already treat

KFF Health News reported on August 25, 2026 that the Medicare GLP-1 Bridge excludes some people with other approved uses for these drugs. The federal pilot offers some enrollees obesity medicine for $50 per month. NPR distributed Jackie Fortiér’s report to public radio stations.

The Bridge is an 18-month demonstration run by the Centers for Medicare and Medicaid Services through a contractor. It began in July 2026 and covers three products: Wegovy, Zepbound in the KwikPen form, and the oral drug Foundayo.

Eligible people with Part D coverage pay $50 per month. These fills sit outside the normal Part D payment system. The annual deductible does not apply. The $50 also does not count toward Part D out-of-pocket totals, and Extra Help does not reduce it.

The $50 price applies when the drug is used only for weight loss.

A body mass index of 35 or higher qualifies on weight alone. A BMI from 27 through 34 requires certain conditions, such as prediabetes or cardiovascular disease.

Different rules apply when the prescription treats a condition already covered under Part D. Examples include type 2 diabetes and moderate to severe obstructive sleep apnea. Those applicants return to their Part D plan. KFF reported monthly copays from about $200 to more than $600 on that route.

KFF estimates that about 5.9 million Medicare enrollees fall outside the pilot. It estimates that about 3.8 million people qualify. KFF projected an 18-month cost near $3.3 billion if one-quarter enrolled. The projection rises toward $10 billion if three-quarters enrolled.

The story follows Jeff La Marca, a 68-year-old retiree in New Jersey, whose application was turned down because of severe obstructive sleep apnea. A CMS spokesperson, Timothy Foster, said the program has let thousands of eligible beneficiaries get GLP-1 medications for weight loss.

A denial needs the plan's stated reason

If Medicare denied your Bridge application, first get the plan or Bridge contractor's stated reason. Ask whether Part D covers the drug for your diagnosed condition. Then confirm with the prescriber which diagnosis was submitted.

An indication is a condition that a regulator has approved a medicine to treat. A diagnosis in the medical record does not explain every denial. Changing one claim field also does not guarantee eligibility. Coverage can depend on the plan's drug list, prior authorization rules, and other requirements.

The $50 payment does not count toward true out-of-pocket spending. Medicare uses that measure to track covered spending toward the annual Part D limit. Bridge payments therefore do not move a member toward that limit.

The exclusion is a coverage rule, not a verdict

The exclusion is not a clinical judgment about whether GLP-1 medicines help people with diabetes or sleep apnea. It reflects a pilot designed around coverage that already exists in Part D.

The 5.9 million and 3.8 million figures are KFF estimates, not CMS enrollment counts. The multi-billion-dollar totals are scenarios based on assumed enrollment, not official budget figures.

The Bridge is a temporary pilot, not a permanent Medicare benefit. CMS has already moved its end date once, and the rules can change again. Nothing here is a reason to start, stop, or switch a medication.